deltatrials
Completed PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT02967640

Does Subacromial Injection With Glutamate Receptor Antagonist, Ketamine, Attenuate Pain in Rotator Cuff Tendinopathy?

Does Subacromial Injection With Glutamate Receptor (NMDAR) Antagonist, Ketamine, Attenuate Pain in Rotator Cuff Tendinopathy?

Sponsor: Helse Møre og Romsdal HF

Interventions Ketalar NaCl 9%
Updated 14 times since 2017 Last updated: Aug 18, 2025 Started: May 30, 2018 Primary completion: Dec 30, 2024 Completion: Dec 30, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2/PHASE3 clinical study on Chronic Pain and Rotator Cuff Tendinitis, this trial is completed. The trial is conducted by Helse Møre og Romsdal HF and has accumulated 14 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Jan 2018 · 12 months · monthly snapshot~Jan 2018 – ~Mar 2018 · 59 days · monthly snapshot~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Sep 2019 · 15 months · monthly snapshot~Sep 2019 – ~Feb 2020 · 5 months · monthly snapshot~Feb 2020 – ~Jan 2021 · 11 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Apr 2022 · 13 months · monthly snapshot~Apr 2022 – ~Mar 2023 · 11 months · monthly snapshot~Mar 2023 – ~Jul 2024 · 16 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Mar 2025 · 6 months · monthly snapshot~Mar 2025 – ~Sep 2025 · 6 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

14 versions recorded
  1. Sep 2025 — Present [monthly]

    Completed PHASE2/PHASE3

    Status: UnknownCompleted

  2. Mar 2025 — Sep 2025 [monthly]

    Unknown PHASE2/PHASE3

    Status: RecruitingUnknown

  3. Sep 2024 — Mar 2025 [monthly]

    Recruiting PHASE2/PHASE3

  4. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE2/PHASE3

    Phase: PHASE2_PHASE3PHASE2/PHASE3

  5. Mar 2023 — Jul 2024 [monthly]

    Recruiting PHASE2_PHASE3

Show 9 earlier versions
  1. Apr 2022 — Mar 2023 [monthly]

    Recruiting PHASE2_PHASE3

  2. Mar 2021 — Apr 2022 [monthly]

    Recruiting PHASE2_PHASE3

  3. Jan 2021 — Mar 2021 [monthly]

    Recruiting PHASE2_PHASE3

  4. Feb 2020 — Jan 2021 [monthly]

    Recruiting PHASE2_PHASE3

  5. Sep 2019 — Feb 2020 [monthly]

    Recruiting PHASE2_PHASE3

  6. Jun 2018 — Sep 2019 [monthly]

    Recruiting PHASE2_PHASE3

  7. Mar 2018 — Jun 2018 [monthly]

    Recruiting PHASE2_PHASE3

  8. Jan 2018 — Mar 2018 [monthly]

    Recruiting PHASE2_PHASE3

    Status: Not Yet RecruitingRecruiting

  9. Jan 2017 — Jan 2018 [monthly]

    Not Yet Recruiting PHASE2_PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Helse Møre og Romsdal HF
Data source: Helse Møre og Romsdal HF

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations